Therapeutic adverse events during first-line treatment, using CTCAE criteria v5.0
| Adverse events . | N . | Grade 1–2 . | Grade 3–4 . | % . |
|---|---|---|---|---|
| Vertebral collapse | 4 | 4 | 3.9 | |
| Fractured rib | 1 | 1 | 1 | |
| Intracranial bleeding | 6 | 5 | 1 | 5.8 |
| Other location bleeding | 5 | 5 | 4.9 | |
| Wound dehiscence | 1 | 1 | 1 | |
| Venous thromboembolic events | 8 | 6 | 2 | 7.8 |
| Thrombocytopenia ≥ grade 3 | 24 | 0 | 24 | 23.2 |
| Neutropenia ≥ grade 3 | 7 | 0 | 7 | 6.8 |
| Lymphopenia ≥ grade 3 | 15 | 0 | 15 | 14.6 |
| Anemia | 3 | 2 | 1 | 2.9 |
| Infection without agranulocytosis | 17 | 15 | 2 | 16.5 |
| Arterial hypertension | 2 | 1 | 1 | 1.9 |
| Fatigue grade ≥ 3 | 9 | 9 | 8.7 | |
| Cognitive impairment | 1 | 1 | 1 |
| Adverse events . | N . | Grade 1–2 . | Grade 3–4 . | % . |
|---|---|---|---|---|
| Vertebral collapse | 4 | 4 | 3.9 | |
| Fractured rib | 1 | 1 | 1 | |
| Intracranial bleeding | 6 | 5 | 1 | 5.8 |
| Other location bleeding | 5 | 5 | 4.9 | |
| Wound dehiscence | 1 | 1 | 1 | |
| Venous thromboembolic events | 8 | 6 | 2 | 7.8 |
| Thrombocytopenia ≥ grade 3 | 24 | 0 | 24 | 23.2 |
| Neutropenia ≥ grade 3 | 7 | 0 | 7 | 6.8 |
| Lymphopenia ≥ grade 3 | 15 | 0 | 15 | 14.6 |
| Anemia | 3 | 2 | 1 | 2.9 |
| Infection without agranulocytosis | 17 | 15 | 2 | 16.5 |
| Arterial hypertension | 2 | 1 | 1 | 1.9 |
| Fatigue grade ≥ 3 | 9 | 9 | 8.7 | |
| Cognitive impairment | 1 | 1 | 1 |
Values in italic are for percentages of patients for each adverse event.
Therapeutic adverse events during first-line treatment, using CTCAE criteria v5.0
| Adverse events . | N . | Grade 1–2 . | Grade 3–4 . | % . |
|---|---|---|---|---|
| Vertebral collapse | 4 | 4 | 3.9 | |
| Fractured rib | 1 | 1 | 1 | |
| Intracranial bleeding | 6 | 5 | 1 | 5.8 |
| Other location bleeding | 5 | 5 | 4.9 | |
| Wound dehiscence | 1 | 1 | 1 | |
| Venous thromboembolic events | 8 | 6 | 2 | 7.8 |
| Thrombocytopenia ≥ grade 3 | 24 | 0 | 24 | 23.2 |
| Neutropenia ≥ grade 3 | 7 | 0 | 7 | 6.8 |
| Lymphopenia ≥ grade 3 | 15 | 0 | 15 | 14.6 |
| Anemia | 3 | 2 | 1 | 2.9 |
| Infection without agranulocytosis | 17 | 15 | 2 | 16.5 |
| Arterial hypertension | 2 | 1 | 1 | 1.9 |
| Fatigue grade ≥ 3 | 9 | 9 | 8.7 | |
| Cognitive impairment | 1 | 1 | 1 |
| Adverse events . | N . | Grade 1–2 . | Grade 3–4 . | % . |
|---|---|---|---|---|
| Vertebral collapse | 4 | 4 | 3.9 | |
| Fractured rib | 1 | 1 | 1 | |
| Intracranial bleeding | 6 | 5 | 1 | 5.8 |
| Other location bleeding | 5 | 5 | 4.9 | |
| Wound dehiscence | 1 | 1 | 1 | |
| Venous thromboembolic events | 8 | 6 | 2 | 7.8 |
| Thrombocytopenia ≥ grade 3 | 24 | 0 | 24 | 23.2 |
| Neutropenia ≥ grade 3 | 7 | 0 | 7 | 6.8 |
| Lymphopenia ≥ grade 3 | 15 | 0 | 15 | 14.6 |
| Anemia | 3 | 2 | 1 | 2.9 |
| Infection without agranulocytosis | 17 | 15 | 2 | 16.5 |
| Arterial hypertension | 2 | 1 | 1 | 1.9 |
| Fatigue grade ≥ 3 | 9 | 9 | 8.7 | |
| Cognitive impairment | 1 | 1 | 1 |
Values in italic are for percentages of patients for each adverse event.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
